Synopsis Juin 2018

SYNOPSIS 2nd Boston ● Paris Biotechnology Summit Boston Exchange Conference Center, Sunday 3 June 2018

The 2nd Boston/Paris Biotechnology Summit was held on Sunday 3 June 2018 at the Boston Exchange Conference Center, just prior to the 2018 BIO Convention held in Boston MA. The Boston – Paris Biotechnology Summit is an exclusive, trans-Atlantic bridge designed to foster innovative synergies between biotech and pharma companies, healthcare-focused cities and regional clusters, and institutional, philanthropic and strategic investors.

The Summits is designed to spark projects, financing and strategic deals to solve unmet medical needs and improve patient lives globally. The 2018 Summit was managed by an Organizing Committee with support from an Expert Advisory Group. Over 200 attendees registered for the Summit (no-shows of only <10%), representing 135 organizations based in Atlanta, Bordeaux, Chicago, Lille, Limoges, London, Lyon, Miami, Nancy, Montreal, New York and Greater NY Area, Toulouse, Vancouver, etc.

The majority was split 50%/50% between France and the USA. We counted close to 100 CEOs, decision makers or equivalent level I attendance. The BOSTON-PARIS Biotechnology Summit is an independent initiative supported by a panel of professionals from the biotech industry on both sides of the Atlantic. It seeks to establish relationships between Boston and French, European and international players and to stimulate and sustain synergies in investment, science, « market access » and regulatory practices.

The efficient transfer of French biotech companies to the US, particularly in the Greater Boston area – the industry’s « Worldwide Hub » – demonstrates how these firms have matured in the life sciences. The aim of the Boston-based 2018 Organizing Committee (Youssef Bennani PhD, Soheila Gharakhanian, Shahin Gharakhanian MD, DPH, Frederic E “Rick” Pierce II,) was thus establish « Win-Win » relationships in both directions.

The first Summit had been held in May 2017 at the Institut Pasteur in Paris, France. In two years, the Summit Co-Founders and Organizing Committees have achieved the following milestones:

1) The Summit has become the premiere French-American biotechnology event held on a single day,

2) It offers wide-ranging knowledge and technical content (clinical trials, KOL relationships, regulatory strategy, Boston Ecosystem, market entry strategies, etc.),

3) Vision, strategic awareness and networking focus for start-ups. Media coverage of the 2018 event included two press releases in Boston (30 May) and Paris (17 April), as well as Linked In postings and cover-page headlines in the widely read and referenced French news magazine “Biotech Finances” [No. 813, dated 28 May 2018].

The 2018 program and content were determined after research and feedback from the biotechnology community. This year’s central theme was “From the Promise of Raising Capital to the Reality of Clinical Trials”. The Organizing Committee, (Soheila Gharakhanian, Shahin Gharakhanian MD, Rick Pierce, speaking) laid down the format for the event, and official representatives from the City of Boston (Krista Zelatores, Chief of Staff for Economic Development to the Mayor of Boston) and the Consulate General of France in Boston (Valery Freland, Consul General) opened the Summit.

The 2018 Vision on Science and Business Strategy lectures were given by the three leaders in the field:

o David Meek, CEO Ipsen, Paris FR & Cambridge MA: Trans-Atlantic Synergy: My Vision and Our Practice at Ipsen

o Robert G. Urban, PhD, Global Head, Johnson & Johnson Innovation, Boston, MA: Healthcare Innovations, Trends, Challenges and Aspirations

o Mark Murcko, PhD, Drug Hunter, Pharmaceutical Executive, Mentor, Disruptive Technology Advocate, Sr. Lecturer at MIT, CSO Relay Therapeutics, Cambridge MA: How I Hunt Drugs in Boston.

US Roadmap 1 involved a panel focused on Academic Thought Leaders, Clinical Trials and Collaboration Panel:

o Academic, start-up and major pharma viewpoints o The “Boston Model” in R&D, Clinical Development? o The role of academic experts in biotech start-ups?

Panelists:

  • Professor Kenneth Kaitin, PhD, Director CSDD: Center for Study of Drug 
Development, TUFTS University, Boston MA (Chair)
  • Camilla “Cami” Graham, MD, MPH BIDC Medical Center, Harvard Medical 
School, Boston MA, Trek Therapeutics, Cambridge MA
  • Joseph Merola, MD, MMSc, Director of Clinical Trials and Center for Skin and 
Related Musculoskeletal Diseases, BWH, Harvard Medical School, Boston MA
  • Robert, G Urban, PhD, Global Head, Johnson & Johnson 
Professor K. Kaitin summarized the characteristics of a dynamic regional cluster based on experience in MA as follows (alphabetical order):
  •   A culture of creativity, open-mindedness and collaboration
  •   Innovative small pharma/biotech companies and start-ups
  •   Investor and VC base
  •   Large Pharma, significant presence
  •   Local government commitment and support
  •   Universities, medical centers, teaching hospitals. 
All participants engaged in very intensive networking during the lunch period.

US ROADMAP 2 involved a panel focused on Regulatory Strategy: 
FDA Update Circa 2018
 – Pragmatic EMA/FDA comparisons – The need for strategic regulatory operations.

Panelists

  • Moderator: Emmanuelle Trombe, partner at 
McDermott, Will & Emery (MWE), Paris, FR
  • Speakers:
  •  Mark De Rosch, PhD Senior Vice President, Regulatory Affairs and Quality Assurance, Nightstar Therapeutics, Lexington MA
  • Veleka R. Peeples-Dyer, Co-Leader, FDA Practice, Life Sciences Industry Group, McDermott, Will & Emery.

GLOBAL ROADMAP 3 (Panel #3) focused on a US Entry & Funding Forum: Selected Company Pitches to a Boston Panel of Executives, Experts & Investors

Panelists: 
Pravin Chaturvedi, PhD (Chair), CEO and Co-Founder, Oceanyx Pharmaceuticals, SAB (Scientific Advisory Board), Napo Pharmaceuticals, Woburn MA

  • Cynthia “Cindy” Lander, PhD, CEO Moerae Matrix. Partner, Nascent 
Enterprises, Venture Catalyst Partnership, Greater New York Area, NY
  • Nicola La Monica, PhD, Senior Director, Infectious Disease Scientific Innovation at Janssen, Pharmaceutical Companies of Johnson & Johnson, 
Boston MA
  • Michael Nowak, MBA, Managing Partner, Nowak Ventures LLC, Registered 
Representative (Investment Banking), Wellesley, MA
  • Kevin J. Scanlon, PhD, Investment Advisor, Sky Venture Group, Professor of 
Practice, Northeastern University, Boston MA
  • Patrick Tricoli, PharmD, MBA, CEO Nanobiotix USA, Nanobiotix Corp., 
Cambridge MA
  • Jean-Marie Vallet, PhD, MBA, Representing Launchpad Venture Group LLC, 
Boston MA

Companies pitching, in alphabetical order:

  • 1)  Tamer Mohamed, CEO Aspect Biosystems, Vancouver, Canada 
https://www.aspectbiosystems.com
  • 2)  Pascal Descargues, CEO Genoskin, Toulouse FR (Liaison Office: Boston/Salem MA) https://www.genoskin.com
  • 3)  Alexander Levert, CEO Osivax, Lyon Fr 
osivax.com
  • 4)  Nader Yaghoubi MD, PhD, CEO Pathmaker Neurosystems, Boston MA (Liaison Office Paris Fr)
com
  • 5)  Ann Kwong, PhD, CEO Trek Therapeutics, Cambridge MA 
com
  • 6)  Alain Lemproye, CEO Yposkesi Genopole, Évry Fr 
yposkesi.com

GLOBAL ROADMAP 3 (Panel #4) focused on EU (and US) Market Entry

Panelists:

Moderator: Julius Steffen Manager, Bionest Partners, Paris FR/New York USA

Francis Marsland, Head of Business Development, Vicarius Pharma AG, Switzerland

Sandford D. Smith, Chairman & Founder, Global BioLink LLC.

Rogerio Vivaldi, MD, Executive Vice-President, Bioverativ – a Sanofi Company.

 

The 2018 Organizing Committee would like to thank all the participants, the City of Boston, the Consulate General of France, our generous Sponsors (BIONEST Partners, IPSEN, MWE: McDermott Will Emery,4Clinics, Nanobiotix, CPL Physicians, as well as, Genopole & Clintec), Supporting Organizations from the Commonwealth of Massachusetts and France, and the 2018 team, including our reception desk volunteers and the Boston Exchange Conference Center.

 

 

2018 Boston.Paris Biotechnology Summit SYNPOSIS

SYNOPSIS

 

_________________________________________________

SYNOPSIS

1st Boston ● Paris Biotechnology Summit ®

_________________________________________________

 

The mission of the 1st Boston Paris Biotechnology Summit™ was to act as a novel catalyst to provide facilitative leadership for talents in both cities and thus foster energies and synergies, spark new projects and generate funding opportunities.

This successful summit was held on 18 May 2017, 8hr-19hr, in the historic Amphitheatre Duclaux at Institut Pasteur in Paris, France. This event was an initiative by and for professionals that was co-founded by Dr Shahin Gharakhanian, Pharmaceutical Medicine Expert (LLC) and Soheila Gharakhanian, Blend of Concept LLC, both based in Cambridge MA. The Organizing Committee (OC) comprised Laure Berliner, Pharm.D, PhD, Market Research Expert (Lexington MA), Jacques-Bernard Taste, Biotech-Finances (Paris/Lyon/Montreal) and the co-founders. The OC was represented in Paris by the Sup’Biotech Junior Enterprise and the Blue Yellow Company. The summit was inaugurated by Professor Christian Bréchot, President of Institut Pasteur followed by a message from the Commonwealth of Massachusetts (Travis McCready, CEO of MALSC: Massachusetts Life Sciences Center, and, Nam Pham, Assistant Secretary, MOITI: Office of International Trade & Investment).

Close to 300 professionals registered for the event, and included executives and CEOs, R&D, BD and other Life Sciences Directors from the biotechnology industry, directors from pharmaceutical firms, academic experts and opinion leaders, institutional representatives, and investors and actors from financial platforms, consultancies, the legal and regulatory affairs fields and the French media.

Attendees from the core cities of Boston and Paris were in the majority, but participants also came from Brussels, major French cities (Lyon, Montpellier, Marseille, and Toulouse), London, Montreal and New York.

The content was designed with input from a Program Advisory Board comprising equal numbers of leaders and experts from Boston/Cambridge and Paris following a needs assessment and pre-test with Paris-based companies. The Faculty was made up of two session chairpersons, three moderators and ten speakers. The Program followed three themes/tracks: (1) Innovation and Strategy, (2) Funding Strategy and (3) Implementing Strategy, with a closing keynote review to bring it all together (the French “synthèse”).

Chairing the morning session, Maryvonne Hiance of France Biotech pointed out that France ranks top in the number of publically-traded companies in Europe and 2nd globally after NASDAQ, and the top ten public biotech and medtech companies represent a market capitalization of €7.9 Billion. The USA leads in terms of French biotech and medtech subsidiaries, half of international affiliates and partnerships. Overall, France has 600 Biotech and 1300 Medtech companies. Chairing the afternoon session, Frederick E. “Rick” Pierce II described the roadmap “From Science to Business” with particular focus on Boston. He concluded that major challenges lie ahead of an entrepreneur and the data are indicative of high failure rates. Entrepreneurship therefore requires multi-disciplinary teams and skills, highly selective processes and preparation to beat chance. He urged entrepreneurs to be passionate, work smart and have fun! Well-prepared minds and serendipity can beat chance. The first theme started with a keynote lecture from Stephan Bancel of Moderna Therapeutics gave the opening keynote “Moderna, or an Integrated Approach to Strategy, Innovation and Funding”. He emphasized that building a business and creating value in biotech implied the management of not only biology and technology risks but also those of a financial and operational nature. The second keynote speaker in this theme was Youssef Bennani from Vertex Pharmaceuticals who discussed “Threading with Innovation from the Lab to the Market”. He defined innovation as it stands circa 2017 and future needs in R&D, taking the growth of his company in market cap as his example. This session was followed by a Panel moderated by Pierre-Louis Germain (Biotech-Finances) during which the speakers were joined by Rafaèle Tordjman from Sofinova.

The lunch and afternoon periods enabled the Sponsors to exhibit and network; this event would not have been possible without their support. The Platinum Sponsors were MWE (McDermott Will and Emery) and BIONEST Partners; the Gold sponsor was 4Clinics. Silver sponsors included VCLS, Charles River and CPL Physicians. Corporate/Biotechnology Circle: Medicen, Genopole and KPL. Lunch was offered by Pact & Partners. Friends circle sponsors are listed in the meeting booklet.

The <Entrepreneurs Forum> enabled seven companies (Crescentia, DaVolterra, Genoskin, ICDD, Keyrus, Pathmaker, Surgimab) to present their products and activities and in particular to interface with investors.

The afternoon session involved the presentation of practical takeaways on two corporate cases [Christophe Bancel for Gecko Biomedical and Laurent Levy for anobiotics]. Panel experts then made presentations that were followed by a discussion with the audience.

Funding was the focus of the first panel moderated by Julius Steffen of Bionest Partners. Vanessa Elharrar (former NIH Director) talked about NIH funding and collaboration in detail, focusing in particular on several points: partnerships with those who have obtained NIH funds, identifying contemporary biomedical gaps and their public health relevance, and the need to always consult with NIH program officials on biomedical ideas, projects, RFAs and proposals before submitting grant applications. Private funding presentations followed from Sofia Ioannidou of EdRIP (Edmond de Rothschild Investment Partners) and Samuel Murphy from Biopharma Capital, who presented their visions from Paris and Boston, respectively. Stable venture financing in Europe reaches around $1 billion a year in the Biotech field; this included a significant rise in European Biotech IPOs in 2014, with a decline which was less steep than that seen in the US. Boston is the largest biotech hub in the US [$3.1 billion], and mapping of the city reveals a not only marked density of high-profile institutional venture firms clustered in a relatively limited area but also the fact that Boston-based investors tend to invest in Boston-based companies.

Implementing strategy was the second topic, addressed during a workshop moderated by Bruno Lucidi, a former pharmaceutical executive who now works at the Wallonia Export Investment Agency. Jennifer Bock, Attorney, McDermott Will and Emery (Boston) discussed legal strategy. She covered a variety of legal topics: corporate and tax structure, intellectual property, raising capital, employment benefits/executive compensation, commercial and strategic transactions, regulatory and government affairs, the management of claims and exposure to litigation. Greg Mannix from Life Sciences Nation (Boston) then discussed the global aspects of funding and his conclusion focused on the following points: it is necessary to prepare, budget for, plan and execute your fundraising campaign by mobilizing the proper resources; to consider a global target list of investors to improve your chances and to reach out to investors when they are a fit for your technology/stage of development.

David Meek from IPSEN ended the meeting with a keynote overview of Boston and Paris scientific potentials and his company’s experience, and his conclusion was clear as to the need to “foster innovation for patients using the R-D-C model: Research investment with selective focus, Development powerhouse and Commercial powerhouse”. He ended by reminding all the professionals in the audience that “Patients Can’t Wait”!

 

References & Further Reading

  • Bennani Y. Drug discovery in the next decade: innovation needed ASAP.Drug Discovery Today, June 2011.
  • Boston Paris Biotechnology Summit Booklet: https://drive.google.com/open?id=0BzbkxZxp8WWjazBQUXVBRXpXb2c
  • Dossier Boston Biotech-Finances. Boston : comment gagner les sommets avec les clefs francophones ? BIOTECH FINANCES, No.719, Avril 2016, pages 5-7.
  • Gauriau B. Paris, future capitale de la biotech ? Boursorama 23/05/2017 http://www.boursorama.com/actualites/paris-future-capitale-de-la-biotechf0efb6cc6e1f19f2f4dbe517aaa522fd
  • La Bourse et La Vie.com – Interview Shahin Gharakhanian, 21/4/2017
  • G.P. Pisano: Science Business. The Promise, The Reality and the Future ofBiotech. Harvard Business School Press: Boston, 2006
  • Mullard A. An Audience with Stephane Bancel. Nature Reviews. Drug Discovery. Vol. 14. June 2015. www.nature.com/reviews/drugdisc.
  • Ramsey BW, Nepom GT, Lonial S. Academic, Foundation and Industry Collaborations in Finding New Therapies. New England Journal of Medicine 2017; 376:1762-9.
  • Revenue Française.com – Interview Shahin Gharakhanian, 19/4/2017

 

Télécharger le pdf / Download the file

Paris, future capitale de la biotech ?

Paris, future capitale de la biotech ?

Boursorama le 23/05/2017 à 18:55

La 1ère édition du Paris-Boston Summit

Pendant que la ville de Paris bataille pour accueillir les Jeux Olympiques de 2024, un autre combat s’y mène, moins médiatique mais au moins aussi important. Le 18 mai, entrepreneurs Français et Américains se rencontraient à l’occasion du premier Boston/Paris Biotechnology Summit. L’objectif de l’évènement : « Rassembler des acteurs majeurs de la biotechnologie » et faire de Paris l’un des premiers centres de la biotechnologie mondiale.

 

Lire l’article

 

 

Communiqué de Presse – 29 Mars

 

 

BOSTON-PARIS Biotechnology Summit™,

1ère édition du Premier Evénement d’Echange Franco-Américain,

le 18 mai 2017 à l’Institut Pasteur, Paris 75015

 

Paris, France – 29 mars 2017 – The BOSTON-PARIS Biotechnology Summit, conférence internationale d’échanges regroupant les principaux acteurs bostoniens et francophones de l’industrie des biotechnologies et de l’investissement, annonce qu’elle tiendra sa première édition à Paris le 18 mai 2017, au sein de l’Amphithéâtre historique Duclaux de l’Institut Pasteur.

 

Read More

Press Release – March 29

 

BOSTON-PARIS Biotechnology Summit™,
1st Edition of the First Franco-American Exchange Event, May 18, 2017 at the Pasteur Institute, Paris 75015.

 

Paris, France – March 29, 2017 -The BOSTON-PARIS Biotechnology Summit, an international trade conference bringing together the major Boston and French-speaking players in the biotech investment industry, is announcing that it will hold its first edition in Paris on May 18, 2017, at the Pasteur Institute’s historic Duclaux Amphitheatre. In the course of the day, nearly 250 professionals will gather for this independent and innovative initiative to discuss the best practices on innovation strategies, on conducting a road show with financiers, and the measures to be implemented to successfully penetrate the U.S. market. Finally, 10 selected startup companies will present their growth strategy before a panel of experts via posters.

Read More

Grand Angle

BOSTON : Comment gagner les sommets avec les clefs francophones ?

Boston, Cambridge, aux yeux des professionnels des biotech et des medtech, mais aussi de toutes les élites mondiales, les deux cités voisines du Masschussets sont « l’endroit où il faut être quand on veut aller vite et réussir« . Cette grappe de la Nouvelle-Angleterre est aux sciences de la vie ce qu’Hollywood est au cinéma. Elle est capable de produire les grandes réussites, les stars du life sciences circus, mais aussi d’engloutir et de détruire les plus beaux espoirs. Dans cet espace compétitif, mieux vaut donc connaître les codes et, pour cela, le français et les réseaux francophones constituent un atout de départ exceptionnel pour les nouveaux arrivants francophones désireux de développeur leur projet à Boston. Nous avons enquêté. Suivez le guide !

Read More